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Scott W Graf1* and Samuel L Whittle2Abstract
We describe a case of skeletal hyperostosis in a 29 year old man presenting with non-inflammatory back pain with
a past history of isotretinoin therapy for acne. The development of skeletal hyperostosis, predominantly of the
spine, has been reported in association with isotretinoin use and has a radiographic picture similar to diffuse
idiopathic skeletal hyperostosis. The prevalence and severity of this condition appears to correlate with duration of
therapy. Isotretinoin is a well-established treatment for severe acne. It is important for the rheumatologist be aware
of this phenomenon when assessing young patients with musculoskeletal symptoms and evidence of radiological
abnormalities.Isotretinoin (13-cis-retinoic acid) is an oral synthetic
vitamin A derivative widely used in the treatment of dis-
orders of keratinization, in particular severe cystic acne.
The development of skeletal hyperostosis has been de-
scribed in association with isotretinoin therapy with
radiological features similar to diffuse idiopathic skeletal
hyperostosis (DISH).
A 29 year old man presented with a two year history
of intermittent mild non-inflammatory pain affecting the
cervical and thoracic spine. He denied any associated
lower back discomfort nor any peripheral arthralgia. His
past history was significant for acne for which he had
been treated with isotretinoin in the past: six months of
therapy nine years previously, a second 6 month course
three years later and a longer three year course finishing
in the year prior to his current presentation. Further his-
tory revealed no past spinal trauma, no symptoms sug-
gestive of inflammatory bowel disease and no preceding
gastrointestinal or genitourinary infection. There was no
personal history of psoriasis but one first degree relative
was affected.
Physical examination revealed a thoracic kyphosis with
a mild painless reduction in cervical and thoracic spine* Correspondence: graffa@hotmail.com
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reproduction in any medium, provided the origrange of motion. Other spinal movements were intact
and painless and no sacroiliac joint tenderness was elic-
ited. There was no peripheral synovitis, enthesitis or
dactylitis and no psoriatic skin or nail changes were
seen.
Blood tests revealed a normal complete blood examin-
ation, biochemistry, C-reactive protein (CRP) and erythro-
cyte sedimentation rate (ESR). HLA-B27 was negative.
Plain radiographs showed inferior facing ossification along
the C3-6 vertebral bodies (Figure 1) with flowing ossifica-
tion along the mid to inferior thoracic spine (Figure 2) and
small bony excrescences at the anterior aspect of the su-
perior endplates of L2-5. Moderate enthesopathy of the
iliac crest was also detected along with moderate bony
osteophytes at the acetabulum bilaterally. No changes of
sacroiliitis were seen. Magnetic resonance imaging (MRI)
of the cervical spine was reported as unremarkable. The
clinical, laboratory and radiological features were felt to
be most consistent with isotretinoin-induced skeletal
hyperostosis.
Skeletal hyperostosis with isotretinoin therapy was first
reported by Pittsley and Yoder in 1983 who described
the development of an ossification disorder resembling
DISH in 4 patients taking isotretinoin for ichthyosis
(Pittsley & Yoder 1983). Further retrospective and pro-
spective studies confirmed this association (Gerber et al.
1984; Pennes et al. 1984; Tangrea et al. 1992). Generally,
higher doses of isotretinoin had been used (2 mg/kgs is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Figure 1 Lateral cervical spine X-RAY showing inferiorly-facing ossification along the C3-6 vertebral bodies.
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indications.
The use of lower dose isotretinoin has also been
shown to be associated with the development of hyper-
ostosis (Tangrea et al. 1992; Kilcoyne et al. 1986). A ran-
domised controlled trial of 139 patients with basal cell
carcinoma given very low dose isotretinoin (10 mg daily)
for 3 years showed significantly more progression of
existing hyperostotic abnormalities and new hyperostotic
involvement in the isotretinoin group compared to pla-
cebo (Tangrea et al. 1992).
The available prospective data has shown that skeletal
hyperostosis can be seen as early as 6 months however
the changes are subtle and of questionable clinical sig-
nificance (Pennes et al. 1984; Kilcoyne et al. 1986). This
raises the possibility that short courses of isotretinoin, as
is currently recommended for the treatment of acne,
may be unlikely to be associated with significant skeletal
changes and morbidity. Follow up studies of patients
treated with isotretinoin for six months or less reveal thedevelopment of only mild asymptomatic hyperostosis
with no significant radiological progression seen over
time (Kilcoyne et al. 1986; Ellis et al. 1988).
It is unclear whether there is a cumulative hyperos-
totic effect of repeated short courses of low dose isotret-
inoin. Ling et al. (2001) reported the development of
spinal hyperostosis in 4 out of 16 patients who had re-
ceived long-term and/or multiple courses of isotretinoin
for acne, equivalent to three four-month courses at
1 mg/kg/day. However the study was retrospective with
no baseline pre-treatment imaging and the cervical spine
was not included, limiting the interpretation of these
data.
The continuous long term use of isotretinoin has been
shown to result in radiographic progression with hyper-
ostosis becoming more extensive and numerous with the
continuation of treatment. Spinal hyperostosis, involving
the anterior vertebral bodies and anterior and posterior
longitudinal ligaments, continues to progress with the
development of appendicular hyperostosis appearing
Figure 2 Lateral X-RAY showing flowing ossification along mid-inferior aspects of the thoracic spine.
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Pennes et al. 1988).
Isotretinoin induced skeletal hyperostosis appears to
be a predominately radiological syndrome with patients
remaining largely asymptomatic unless the condition be-
comes advanced after long term therapy. Mild non-
specific musculoskeletal symptoms have been reported
while on therapy however these do not correlate with
radiographic abnormalities. The radiological features are
similar to DISH with calcification of the anterior longi-
tudinal ligament, bony excrescences at the anterior
corners of the vertebral bodies and hyperostosis at ap-
pendicular entheseal insertions. The cervical spine ap-
pears to be the predominant area involved followed by the
thoracic and lumbar regions. Laboratory investigations areunremarkable (Tangrea et al. 1992; Ellis et al. 1988; Pennes
et al. 1988; Carey et al. 1988).
Isotretinoin is a commonly used treatment for acne.
An awareness of this phenomenon is therefore import-
ant for the rheumatologist when assessing the young pa-
tient presenting with musculoskeletal symptoms with
associated radiological abnormalities.Consent
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